Skip to main content

Table 3 Subgroup analyses of acarbose on lipid profiles in adults

From: The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials

 

NO

WMD (95%CI)

P-value

heterogeneity

P heterogeneity

I2

P between sub-groups

Subgroup analyses of acarbose on serum TG (mg/dl)

Overall effect

71

−13.43 (− 19.20, −7.67)

< 0.001

< 0.001

86.8%

 

Baseline TG (mg/dl)

      

  < 150

27

−8.40 (− 15.24, − 1.57)

0.016

< 0.001

72.6%

0.095

  ≥ 150

44

−17.00 (−24.44, −9.56)

< 0.001

< 0.001

84.8%

Trial duration (week)

      

 <24

34

−7.96 (−18.94, 3.01)

0.155

< 0.001

86.5%

0.150

  ≥ 24

37

− 17.43 (− 24.21, − 10.65)

< 0.001

< 0.001

86.2%

Intervention dose (mg/day)

      

 <300

24

−15.57 (−23.60, −7.53)

< 0.001

< 0.001

61.5%

0.635

  ≥ 300

47

−12.97 (−20.05, − 5.88)

< 0.001

< 0.001

88.5%

Baselin BMI (kg/m2)

      

 Overweight (25–29.9)

10

−14.31 (−21.14, −7.48)

< 0.001

0.329

12.4%

0.849

 Obese (> 30)

52

−15.25 (−22.19, −8.31)

< 0.001

< 0.001

88.5%

Health status

      

 Diabetic

55

−11.04 (−17.11, −4.96)

< 0.001

< 0.001

78.8%

0.137

 Non diabetic

16

−21.03 (−32.71, −9.35)

< 0.001

< 0.001

90.6%

Age (year)

      

 50>

16

−6.48 (−14.13, 1.17)

0.097

< 0.001

69.3%

0.172

 50<

54

−13.66 (−20.57, −6.75)

< 0.001

< 0.001

85.2%

Sex

      

 Both

64

− 13.98 (−20.15, −7.80)

< 0.001

< 0.001

87.8%

0.177

 Female

6

−6.19 (−18.85, 6.47)

0.338

0.072

50.6%

 Male

1

−90.00 (−190.16, 10.16)

0.078

–

–

Subgroup analyses of acarbose on serum TC (mg/dl)

 Overall effect

64

−1.93 (−3.71, −0.15)

0.033

< 0.001

67.0%

 

Baseline TC (mg/dl)

      

  < 200

30

−2.49 (−4.87, − 0.10)

0.041

< 0.001

71.8%

0.602

  ≥ 200

34

−1.51 (− 4.29, 1.25)

0.283

< 0.001

57.6%

Trial duration (week)

      

 <24

33

0.18 (−2.58, 2.96)

0.894

< 0.001

58.6%

0.030

  ≥ 24

31

−3.84 (−6.20, −1.48)

< 0.001

< 0.001

70.0%

Intervention dose (mg/day)

      

 <300

21

0.27 (−2.49, 3.03)

0.849

0.174

22.3%

0.077

  ≥ 300

43

−2.89 (−5.05, −0.73)

0.009

< 0.001

73.5%

Baselin BMI (kg/m2)

      

 Overweight (25–29.9)

10

−4.36 (−8.72, −0.01)

0.050

0.016

55.8%

0.271

 Obese (> 30)

46

−1.63 (−3.79, 0.52)

0.138

< 0.001

71.7%

Health status

      

 Diabetic

52

−1.91 (−3.77, −0.05)

0.044

< 0.001

62.5%

0.858

 Non diabetic

12

−1.33 (−7.36, 4.68)

0.663

< 0.001

79.8%

Age (year)

      

 50>

15

−0.81 (−5.55, 3.93)

0.737

< 0.001

66.6%

0.744

 50<

48

−1.66 (−3.46, 0.14)

0.071

< 0.001

58.5%

Sex

      

 Both

59

−2.25 (−4.11, −0.39)

0.018

< 0.001

68.3%

0.134

 Female

5

1.64 (−3.10, 6.39)

0.498

0.365

7.3%

Subgroup analyses of acarbose on serum LDL (mg/dl)

 Overall effect

53

0.41 (−1.30, 2.14)

0.635

< 0.001

79.3%

 

Baseline LDL (mg/dl)

      

  < 100

9

−3.31 (−13.33, 6.69)

0.186

0.012

59.0%

0.091

  ≥ 100

44

1.08 (−0.91, 3.09)

0.286

< 0.001

81.1%

Trial duration (week)

      

 <24

25

1.96 (−0.01, 3.95)

0.052

0.024

39.3%

0.057

  ≥ 24

28

−1.13 (−3.63, 1.37)

0.375

< 0.001

87.0%

Intervention dose (mg/day)

      

 <300

20

2.40 (−0.59, 5.40)

0.116

< 0.001

63.0%

0.105

  ≥ 300

33

−0.64 (−2.80, 1.50)

0.555

< 0.001

83.5%

Baselin BMI (kg/m2)

      

 Overweight (25–29.9)

8

1.54 (−2.30, 5.39)

0.432

0.168

32.6%

0.719

 Obese (> 30)

40

0.74 (−1.21, 2.71)

0.456

< 0.001

82.0%

Health status

      

 Diabetic

41

0.84 (−1.21, 2.90)

0.420

< 0.001

81.9%

0.404

 Non diabetic

12

−0.76 (−3.93, 2.40)

0.637

0.002

62.6%

Age (year)

      

 50>

11

−1.33 (−6.08, 3.42)

0.583

< 0.001

68.9%

0.409

 50<

42

0.82 (−1.06, 2.72)

0.392

< 0.001

81.1%

Sex

      

 Both

48

0.76 (−1.01, 2.53)

0.400

< 0.001

79.7%

0.264

 Female

5

−5.10 (−15.25, 5.04)

0.324

0.001

78.1%

Subgroup analyses of acarbose on serum HDL (mg/dl)

 Overall effect

64

0.10 (−0.69, 0.91)

0.792

< 0.001

87.2%

 

Baseline HDL (mg/dl)

      

  < 40

12

−0.45 (−2.31, 1.41)

0.636

< 0.001

71.6%

0.522

  ≥ 40

52

0.22 (−0.66, 1.11)

0.620

< 0.001

88.3%

Trial duration (week)

      

 <24

32

−0.16 (−1.89, 1.57)

0.856

< 0.001

91.2%

0.597

  ≥ 24

32

0.35 (− 0.41, 1.11)

0.371

< 0.001

74.0%

Intervention dose (mg/day)

      

 <300

22

−1.20 (−2.35, −0.04)

0.042

< 0.001

68.2%

0.009

  ≥ 300

42

0.80 (−0.17, 1.79)

0.107

< 0.001

88.3%

Baselin BMI (kg/m2)

      

 Overweight (25–29.9)

10

−0.48 (−4.78, 3.80)

0.824

< 0.001

95.5%

0.711

 Obese (> 30)

49

0.33 (−0.41, 1.09)

0.382

< 0.001

79.9%

Health status

      

 Diabetic

51

−0.09 (−1.00, 0.80)

0.833

< 0.001

86.9%

0.462

 Non diabetic

13

0.75 (−1.33, 2.84)

0.478

< 0.001

88.9%

Age (year)

      

 50>

13

−0.19 (−2.44, 2.06)

0.869

< 0.001

82.4%

0.883

 50<

50

−0.00 (− 0.88, 0.86)

0.985

< 0.001

87.1%

Sex

      

 Both

59

−0.04 (−0.87, 0.78)

0.922

< 0.001

87.8%

0.041

 Female

4

3.50 (0.68, 6.32)

0.015

0.163

41.4%

 Male

1

−3.80 (−12.64, 5.04)

0.400

–

–

  1. Abbreviations: BMI body mass index, CI confidence interval, HDL high density lipoprotein, LDL low-density lipoprotein, TC total cholesterol, TG triglyceride, WMD weighted mean differences
  2. Subgroup analyses have done
  3. P < 0.05 was considered a significance and bolded
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us